Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin

INTRODUCTION: The biosimilar SAR341402 insulin aspart (SAR-Asp) was compared to its originator NovoLog®/NovoRapid® insulin aspart (NN-Asp) in terms of efficacy, safety, and immunogenicity, in adults with type 1 or type 2 diabetes switching from different rapid-acting insulin analogs. METHODS: This p...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Viral N., Franek, Edward, Wernicke-Panten, Karin, Pierre, Suzanne, Mukherjee, Bhaswati, Sadeharju, Karita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846644/
https://www.ncbi.nlm.nih.gov/pubmed/33432547
http://dx.doi.org/10.1007/s13300-020-00992-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846644/
https://www.ncbi.nlm.nih.gov/pubmed/33432547
http://dx.doi.org/10.1007/s13300-020-00992-x

Ejemplares similares